Pharmaceutical Technology13m
Risk adjusted net present value: What is the current valuation of I-Mab’s Givastomig?
The revenue for Givastomig is expected to reach an annual total of $48 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...
Pharmaceutical Technology13m
Risk adjusted net present value: What is the current valuation of PTC Therapeutics’s PTC-518?
PTC Therapeutics discovers, develops, and markets medicines for the treatment of rare disorders. Its marketed products include Evrysdi (risdiplam) for spinal muscular atrophy, Translarna (ataluren), ...
Pharmaceutical Technology13m
Risk adjusted net present value: What is the current valuation of Sarepta Therapeutics’s SRP-5051?
Sarepta Therapeutics (Sarepta) discovers and develops unique RNA-targeted medicines to treat rare diseases. The company develops its pipeline products using its multi-platform Precision Genetic ...
Pharmaceutical Technology15m
Risk adjusted net present value: What is the current valuation of Cardiol Therapeutics’s Cannabidiol 1?
Cannabidiol 1 is a small molecule commercialized by Cardiol Therapeutics, with a leading Phase II program in Pericarditis.
Pharmaceutical Technology16m
Risk adjusted net present value: What is the current valuation of AstraZeneca’s Eneboparatide?
Eneboparatide is a recombinant peptide commercialized by AstraZeneca, with a leading Phase III program in Hypoparathyroidism.
Pharmaceutical Technology17m
Risk adjusted net present value: What is the current valuation of Roche’s RG-6641?
RG-6641 is a synthetic peptide commercialized by Roche, with a leading Phase II program in Obesity. According to Globaldata, it is involved in 5 clinical trials, of which 2 were completed, 2 are ...
Pharmaceutical Technology20m
Risk adjusted net present value: What is the current valuation of Ionis Pharmaceuticals’s Zilganersen Sodium?
Ionis Pharmaceuticals (Ionis), formerly Isis Pharmaceuticals, focuses on the discovery and development of RNA-targeted drugs. The company develops medicines to treat various diseases including cancer, ...
Pharmaceutical Technology21m
Risk adjusted net present value: What is the current valuation of Takeda Pharmaceutical’s Danavorexton?
Danavorexton is a small molecule commercialized by Takeda Pharmaceutical, with a leading Phase II program in Obstructive Sleep Apnea.
Pharmaceutical Technology22m
Risk adjusted net present value: What is the current valuation of Intra-Cellular Therapies’s ITI-333?
ITI-333 is a small molecule commercialized by Intra-Cellular Therapies, with a leading Phase I program in Opium (Opioid) Addiction.